TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36000699

Group type: EXPERIMENTAL
Intervention: Finalized Actions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Non-Finalized Actions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control Videos
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reaching phase of feeding and self-care actions
Number of subjects: 19
Study: 36000747

Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS) treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Historical control cohort (PHLF patients not treated with MARS)
Number of subjects: 10
Study: 36000763

Group type: COMPARATOR
Intervention: Listening to music (prerecorded) for 25 to 60 minutes daily for 3 days to 3 months
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Listening to music (prerecorded)
Number of subjects: 1007
Study: 36000783

Group type: EXPERIMENTAL
Intervention: Professional coaching (6 monthly sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed intervention (6 monthly sessions after 6 months)
Number of subjects: 80
Study: 36000794

Group type: EXPERIMENTAL
Intervention: Neoadjuvant apalutamide 240 mg once daily for 12 weeks
Number of subjects: 30
Study: 36000952

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 90
Study: 36001108

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg on day 10 and fluconazole 200 mg once daily on days 11-23, with a single oral dose of fedratinib 100 mg on day 18
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single oral dose of fedratinib 100 mg on day 1
Number of subjects: 16
Study: 36001116

Group type: EXPERIMENTAL
Intervention: Biodistribution and radiation dosimetry studies
Number of subjects: 3
Study: 36001201

Group type: EXPERIMENTAL
Intervention: High relationship control (RC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Middle relationship control (RC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low relationship control (RC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sexual Relationship Power Scale (SRPS) and its subscales
Number of subjects: 0
Study: 36001228

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg intravenously every 3 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Palliative SBRT (30-50 Gy delivered daily over five fractions per week)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of palliative SBRT and camrelizumab
Number of subjects: 21
Study: 36001236

Group type: EXPERIMENTAL
Intervention: Habit practicing group (exposed group)
Number of subjects: 30
Study: 36001294

Group type: EXPERIMENTAL
Intervention: Aralast NP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aralast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolastin
Number of subjects: 0
Study: 36001426

Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation (atVNS) as an ADD-ON intervention.
Number of subjects: 0
Study: 36001430

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Abstaining AUD patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Relapsing AUD patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy control (CON) subjects
Number of subjects: 88
Study: 36001750

Group type: EXPERIMENTAL
Intervention: High-dose glucagon (1.5 ng/kg/min, t = 270-450 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-dose glucagon (0.65 ng/kg/min, t = 0-270 min)
Number of subjects: 28
Study: 36001857

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 36002204

Group type: EXPERIMENTAL
Intervention: Post lockdown
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spending time sitting
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unhealthy lifestyle
Number of subjects: 40
Study: 36002215

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including health services redesign, clinical staff training, and patient/community engagement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (deprived commune)
Number of subjects: 0
Study: 36002223

Group type: EXPERIMENTAL
Intervention: Evaluation of knowledge, attitudes and beliefs regarding HPV vaccination
Number of subjects: 0
Study: 36002226

Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine
Number of subjects: 19
Study: 36002228

Group type: EXPERIMENTAL
Intervention: Dipstick urinalysis for UTI detection
Number of subjects: 275
Study: 36002243

Group type: EXPERIMENTAL
Intervention: Histotripsy treatment for hepatic tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36002823

Group type: EXPERIMENTAL
Intervention: Chronic Pain (CP)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Anxiety, Depression, PTSD
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Chronic Pain
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Mental Health (anxiety and PTSD)
Number of subjects: 902
Study: 36002841

Group type: EXPERIMENTAL
Intervention: RTS,S vaccination
Number of subjects: 0
Study: 36002847

Group type: EXPERIMENTAL
Intervention: Preference-concordant treatment decisions
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Receipt of a decision aid
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Low tumor risk and age ≥ 60 years
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Attributing a lot of influence to treatment impact on recreation
Number of subjects: 224
Study: 36002874

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS), two one-hour sessions daily for four weeks at suprathreshold intensities.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract).
Number of subjects: 13
Study: 36003379

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMAs)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PD-1 expression after 2 cycles of HMA treatment
Number of subjects: 135
Study: 36003437

Group type: EXPERIMENTAL
Intervention: Preoperative pembrolizumab combined with chemoradiotherapy (PPCT)
Number of subjects: 143
Study: 36003844

Group type: EXPERIMENTAL
Intervention: ProTaper Next
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: WaveOne Gold
Number of subjects: 150

Group type: COMPARATOR
Intervention: Preoperative pain presence
Number of subjects: 150
Study: 36004342

Group type: EXPERIMENTAL
Intervention: Cushing's disease patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study: 36004683

Group type: EXPERIMENTAL
Intervention: Multiplier method for estimating OUD prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persons aged 35-54
Number of subjects: 0
Study: 36004747

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: SDB
Number of subjects: 242
Study: 36004765

Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) added to conservative treatment
Number of subjects: 0
Study: 36005184

Group type: EXPERIMENTAL
Intervention: Inguinal Lymph Node Dissection (ILND)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 66
Study: 36005198

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 0
Study: 36005278

Group type: COMPARATOR
Intervention: HIF stabilisers
Number of subjects: 30994
Study: 36005402

Group type: EXPERIMENTAL
Intervention: Obesity group (BMI ≥ 30 kg/m2)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Non-obesity group
Number of subjects: 188
Study: 36005444

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) at 33 °C for 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 40
Study: 36005642

Group type: EXPERIMENTAL
Intervention: Multispecies Probiotic Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36006068

Group type: EXPERIMENTAL
Intervention: 18F-FET PET/CT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T1-GD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T2-FLAIR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rCBV, K2, b1000, ADC
Number of subjects: 30
Study: 36006288

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 301
Study: 36006468

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) with a 75-g glucose dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postcalorimetric correction procedure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Energy metabolism response to OGTT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Areas under the curve for RER and EE
Number of subjects: 12
Study: 36006568

Group type: EXPERIMENTAL
Intervention: Interferon Gamma Release Assay (IGRA, QuantiFERON® SARS-CoV-2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plaque Reduction Neutralization Test (PRNT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Current anti-spike serological test
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heterologous vaccination scheme
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IGRA and anti-spike serology assays
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Decrease intensity or absence of IGRA response
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Decrease intensity or absence of anti-spike serology
Number of subjects: 80
Study: 36006606

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO + IPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparators (Nivolumab, Ipilimumab, Pembrolizumab, Dabrafenib plus Trametinib, Encorafenib plus Binimetinib, Vemurafenib plus Cobimetinib)
Number of subjects: 0
Study: 36006678

Group type: EXPERIMENTAL
Intervention: Principal Investigator (PI) tool kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of PI tool kit elements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deployment of PI tool kit
Number of subjects: 0
Study: 36006807

Group type: EXPERIMENTAL
Intervention: Memantine (dosage based on weight, ranging from 3 mg to 15 mg per day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 204
Study: 36006879

Group type: COMPARATOR
Intervention: Stage III melanoma
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Stage IIC melanoma
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Stage IIIB melanoma
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Stage IIIC melanoma
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Stage IIID melanoma
Number of subjects: 1054
Study: 36006948

Group type: EXPERIMENTAL
Intervention: Intervention group with evening time management plans and bright light exposure (~6000 lux; 2.5 h) on weekend mornings.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group with no intervention, sleeping as usual.
Number of subjects: 46
Study: 36007102

Group type: EXPERIMENTAL
Intervention: venetoclax + azacitidine
Number of subjects: 127

Group type: COMPARATOR
Intervention: azacitidine
Number of subjects: 127
Study: 36007218

Group type: EXPERIMENTAL
Intervention: Anti-EGFR therapy
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Paired tissue and ctDNA sequencing
Number of subjects: 169
Study: 36007299

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 422
Study: 36007963

Group type: EXPERIMENTAL
Intervention: Trametinib (T) 2 mg/day orally starting 1 week prior to durvalumab (D) 1500 mg intravenously every 4 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tumor tissue flow cytometry at baseline (BL) and early on-treatment (OT) at week 4
Number of subjects: 29
Study: 36008115

Group type: EXPERIMENTAL
Intervention: Positive diagnosis of SSD according to DSM-5 criteria
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Possible SSD diagnosis based on high scores on diagnostic scales
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome criteria
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mood-anxiety disorders screening
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: History of prior SSD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reported past trauma
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-survey for PTSD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-survey for insomnia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psychiatric follow-up
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Work or pay loss
Number of subjects: 50
Study: 36008193

Group type: EXPERIMENTAL
Intervention: Intravesical pembrolizumab (1-5 mg/kg for 2 hours)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravesical pembrolizumab
Number of subjects: 9
Study: 36008198

Group type: EXPERIMENTAL
Intervention: 24-h levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 401

Group type: COMPARATOR
Intervention: 16-h levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 401
Study: 36008559

Group type: EXPERIMENTAL
Intervention: Nordic dietary patterns
Number of subjects: 1057893
Study: 36008819

Group type: EXPERIMENTAL
Intervention: Amino acid-based ORS (VS002A)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard glucose-based WHO-ORS
Number of subjects: 312
Study: 36008843

Group type: COMPARATOR
Intervention: SOD1 proteinopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p62 co-deposition with mutant and wild-type disSOD1 and phosphorylated TDP-43
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wild-type SOD1 and TDP-43 co-deposition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alterations to the subcellular localization of SOD1, TDP-43, and p62
Number of subjects: 0
Study: 36009070

Group type: EXPERIMENTAL
Intervention: Scalp nerve block (SNB) combined with intercostal nerve block (ICNB)
Number of subjects: 88
Study: 36011453

Group type: EXPERIMENTAL
Intervention: Professional Pharmaceutical Service intervention
Number of subjects: 1200
Study: 36011572

Group type: EXPERIMENTAL
Intervention: Primary prevention intervention addressing AYCs' mental health through Blended Learning Networks and a clinical trial in six European countries.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-design and implementation of tailored support intervention resilient to COVID-19 related restrictions.
Number of subjects: 0
Study: 36012052

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 7409

Group type: EXPERIMENTAL
Intervention: 2MACE score
Number of subjects: 7409

Group type: EXPERIMENTAL
Intervention: HAS−BLED score
Number of subjects: 7409

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score ≥3 vs. <3
Number of subjects: 7409
Study: 36012885

Group type: EXPERIMENTAL
Intervention: Adaptive to Position (ATP) workflow
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adaptive to Shape (ATS) workflow
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acute toxicity
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patient-reported treatment experience
Number of subjects: 16
Study: 36012989

Group type: EXPERIMENTAL
Intervention: End stage kidney disease (ESKD)
Number of subjects: 4354

Group type: COMPARATOR
Intervention: Patients without kidney disease
Number of subjects: 4354
Study: 36012997

Group type: EXPERIMENTAL
Intervention: 3D printed models used for simulation in transcatheter PVL closure procedures
Number of subjects: 11
Study: 36013098

Group type: EXPERIMENTAL
Intervention: Novel implant system with low-speed (50 rpm) site preparation instruments used without irrigation and tri-oval, tapered implant.
Number of subjects: 95
Study: 36015302

Group type: EXPERIMENTAL
Intervention: TDM arm (therapeutic drug monitoring)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control arm (standard imatinib management)
Number of subjects: 133
Study: 36015771

Group type: EXPERIMENTAL
Intervention: iPhone App for detecting prefrailty and sarcopenia syndromes, using sit-to-stand muscle power measured through a slow-motion video analysis mobile application in combination with muscle mass (calf circumference or upper mid-arm circumference).
Number of subjects: 400

Group type: COMPARATOR
Intervention: Reference standards for frailty syndrome (Fried's Phenotype) and sarcopenia (EWGSOP2).
Number of subjects: 400
Study: 36016106

Group type: EXPERIMENTAL
Intervention: Ormutivimab + vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRIG + vaccine
Number of subjects: 0
Study: 36016541

Group type: EXPERIMENTAL
Intervention: Direct admission to thrombectomy center
Number of subjects: 650

Group type: COMPARATOR
Intervention: Transfer from another hospital to thrombectomy center
Number of subjects: 650
Study: 36016547

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid pressure dynamics (CSFP) measurements including baseline CSFP, cardiac-driven CSFP peak-to-trough amplitude (CSFPp), and Queckenstedt's test in neutral and reclined head position.
Number of subjects: 7
Study: 36016762

Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin at 0.5 mcg/kg
Number of subjects: 851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study: 36017088

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneous) on top of 10 mg/day rosuvastatin
Number of subjects: 31
Study: 36017287

Group type: EXPERIMENTAL
Intervention: HFA-PEFF score ≥5 group
Number of subjects: 1022

Group type: COMPARATOR
Intervention: HFA-PEFF score <5 group
Number of subjects: 1022
Study: 36017315

Group type: COMPARATOR
Intervention: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in control subjects
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in T2D subjects
Number of subjects: 46
Study: 36017341

Group type: EXPERIMENTAL
Intervention: Tenofovir-lamivudine-dolutegravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36017643

Group type: EXPERIMENTAL
Intervention: FOP patients
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Primary caregivers of FOP patients
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: FOP patients and primary caregivers (≥18 years)
Number of subjects: 463
Study: 36017780

Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 0
Study: 36018235

Group type: EXPERIMENTAL
Intervention: Anifrolumab (300 mg i.v. once every 4 weeks for 48 weeks)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sustained glucocorticoid taper responders
Number of subjects: 375
Study: 36018496

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no rhPTH(1-84))
Number of subjects: 72
Study: 36018712

Group type: EXPERIMENTAL
Intervention: HRV biofeedback devices
Number of subjects: 20
Study: 36027980

Group type: EXPERIMENTAL
Intervention: Meeting screen time guideline (<60 minutes of screen time)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: More minutes of screen time
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Daily physical activity
Number of subjects: 352
Study: 36028065

Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (proton-RT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional radiation therapy (not explicitly mentioned in the study but referenced for comparison)
Number of subjects: 70
Study: 36028193

Group type: EXPERIMENTAL
Intervention: Multilevel intervention including enhanced prenatal care services via telehealth, anti-racism training for providers, and community care maternal safety bundles.
Number of subjects: 540000

Group type: COMPARATOR
Intervention: Pre-intervention period (2016-2019)
Number of subjects: 540000

Group type: EXPERIMENTAL
Intervention: Post-intervention period (2022-2025)
Number of subjects: 540000
Study: 36028357

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab with sub-ablative radiation (8Gyx3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 36028446

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks for 52 weeks
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1902
Study: 36028757

Group type: EXPERIMENTAL
Intervention: Reduced-toxicity conditioning regimen (RTC) using intravenous busulfan (3.2 mg/kg/d for 4 days) and fludarabine (30 mg/m2); specific dosage and duration provided.
Number of subjects: 0
Study: 36028846

Group type: EXPERIMENTAL
Intervention: Chest CT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Genetic testing for FLCN gene
Number of subjects: 88
Study: 36028895

Group type: EXPERIMENTAL
Intervention: Cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 56
Study: 36029028

Group type: EXPERIMENTAL
Intervention: Foundational implementation support (low-touch)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Enhanced implementation support (high-touch)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Implementation intensification model
Number of subjects: 170
Study: 36029527

Group type: EXPERIMENTAL
Intervention: ABBV-383 (administered intravenously over 1-2 hours once every 3 weeks)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ABBV-383 (60 mg dose in dose expansion cohort)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ABBV-383 (≥ 40 mg in dose escalation plus dose expansion cohorts)
Number of subjects: 124
Study: 36029725

Group type: EXPERIMENTAL
Intervention: Fetal exome sequencing (ES) with pharmacogenomics (PGx) results offered as a secondary finding.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) testing results from fetal exome sequencing.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medication administration based on CPIC Level A evidence.
Number of subjects: 40